Biotechnology company Pharming accounced on Wednesday it has obtained a credit facility to the tune of €10m.

The credit will be used as a bridging loan to cover a US study into its drug Ruconest, used in treating and protecting against injuries caused by ischemia and reperfusion.
Ischemia is a restriction in the blood supply caused by factors in blood vessels. Reperfusion occurs when the blood supply returns after a period of ischemia, causing tissue damage.
A US patent for research into the drug was issued in December 2011.
Ruconest, known as Rhucin in the US, is Pharming’s flagship drug and is already on the market in several European countries.